Charles P D, Davis T L
Department of Neurology, Vanderbilt University School of Medicine, Nashville, Tenn., USA.
South Med J. 1996 Sep;89(9):851-6. doi: 10.1097/00007611-199609000-00002.
Parkinson's disease (PD) is a common neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and loss of postural reflexes. Although the agents available for symptomatic treatment now allow most parkinsonian patients to live a normal life-span, these patients become progressively unable to participate in social functions, perform activities of daily living, and work. Therapy for PD may be associated with many complications that contribute to these disabilities. For this reason, education is helpful for the patient newly diagnosed with PD. Over the past 6 years, three new medications (selegiline, pergolide, and controlled-release levodopa) have been approved for use in Parkinson's disease. Other agents now available for the treatment of psychiatric illness may also be helpful in selected cases of PD. With this in mind, we review the commonly prescribed drugs and outline a rational plan for treatment of parkinsonism.
帕金森病(PD)是一种常见的神经退行性疾病,其特征为震颤、僵硬、运动迟缓以及姿势反射丧失。尽管目前用于对症治疗的药物能使大多数帕金森病患者享有正常寿命,但这些患者逐渐无法参与社交活动、进行日常生活活动以及工作。帕金森病的治疗可能会引发许多导致这些功能障碍的并发症。因此,对新诊断出帕金森病的患者进行教育很有帮助。在过去6年里,三种新药(司来吉兰、培高利特和控释左旋多巴)已获批用于帕金森病治疗。目前可用于治疗精神疾病的其他药物在某些帕金森病病例中可能也有帮助。考虑到这一点,我们回顾常用药物并概述帕金森病的合理治疗方案。